Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
Susin Park, Nam Kyung Je, Dong Wan Kim, Miran Park, MD Jeonghun Heo
Journal of Korean Medical Science, doi:10.3346/jkms.2022.37.e102
Background: Regdanvimab has decreased the time to clinical recovery from coronavirus disease 2019 (COVID-19) and lowered the rate of oxygen therapy according to the results from phase 2/3 randomized controlled trial. More information is needed about the effects and safety of regdanvimab. Methods: We analyzed data for patients with high-risk mild or moderate COVID-19 being admitted to Busan Medical Center between December 1, 2020 and April 16, 2021. A propensity score (PS) matched analysis was conducted to compare patients treated with and without regdanvimab. The primary outcome was in-hospital death or disease aggravation which means the need for oxygen therapy (low-or high-flow oxygen therapy and mechanical ventilation) and secondary outcomes comprised the length of hospital stay and adverse reactions. Results: Among 1,617 selected patients, 970 (60.0%) were indicated for regdanvimab. Of these, 377 (38.9%) were administered with regdanvimab. Among a 1:1 PS-matched cohort of 377 patients each treated with and without regdanvimab, 19 (5%) and 81 (21.5%) reached the composite outcome of death, or disease aggravation, respectively (absolute risk difference, -16.4%; 95% confidence interval [CI], -21.1, -11.7; relative risk difference, 76.5%; P < 0.001). Regdanvimab significantly reduced the composite outcome of death, or disease aggravation in univariate (odds ratio [OR], 0.194; 95% CI, 0.112-0.320; P < 0.001) and multivariableadjusted analyses (OR, 0.169; 95% CI, 0.095-0.289; P < 0.001). The hospital stay was shorter for the group with than without regdanvimab. Some hematological adverse reactions were more frequent in the group without regdanvimab, but other adverse reactions did not significantly differ between the groups. Conclusion: Regdanvimab was associated with a significantly lower risk of disease aggravation without increasing adverse reactions.
SUPPLEMENTARY MATERIALS Supplementary Table 1 Missing baseline laboratory data in propensity score-matched cohort
Click here to view
Supplementary Table 2 Associations between regdanvimab and primary endpoint in PS-matched and overall cohorts
Click here to view
Supplementary Table 3
Clinical outcomes in overall cohort Click here to view Supplementary Fig. 1 Distribution of covariates before and after propensity matching study patients who were and were not treated with regdanvimab. Click here to view Supplementary Fig. 2 Standardized mean differences in unadjusted and adjusted cohorts.
Click here to view
References
Baum, Fulton, Wloga, Copin, Pascal et al., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science,
doi:10.1126/science.abd0831Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019, Anesth Analg,
doi:10.1213/ANE.0000000000005292Daniels, Sitapati, Zhang, Zou, Bui et al., Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients, Am J Cardiol,
doi:10.1016/j.amjcard.2020.09.012Eom, Ison, Streinu-Cercel, Săndulescu, Preotescu et al., Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection, Res Sq,
doi:10.21203/rs.3.rs-296518/v1Fosbøl, Butt, Østergaard, Andersson, Selmer et al., Association of angiotensinconverting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality, JAMA,
doi:10.1001/jama.2020.11301Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ,
doi:10.1186/s13293-020-00304-9Gupta, Madhavan, Poterucha, Defilippis, Hennessey et al., Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19, Nat Commun,
doi:10.1038/s41467-021-21553-1Hj, Kim, Kang, Yang, Lee, Prediction of COVID-19-related mortality and 30-day and 60day survival probabilities using a nomogram, J Korean Med Sci,
doi:10.3346/jkms.2021.36.e248Jia, Gong, Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?, J Korean Med Sci,
doi:10.3346/jkms.2021.36.e124Kim, Ryoo, Huh, Joo, Kim et al., Revised Korean Society of Infectious Diseases/ National Evidence-based Healthcarea collaborating agency guidelines on the treatment of patients with COVID-19, Infect Chemother,
doi:10.3947/ic.2021.0303Kim, Ryu, Lee, Kim, Seo et al., A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun,
doi:10.1038/s41467-020-20602-5Lam, Chow, Vo, Hou, Li et al., Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome, J Infect Dis,
doi:10.1093/infdis/jiaa447Lee, Choe, Jeong, Kim, Kim et al., Importation and transmission of SARS-CoV-2 B.1.1.529 (Omicron) variant of concern in Korea, November 2021, J Korean Med Sci,
doi:10.3346/jkms.2021.36.e346Li, Xu, Yu, Wang, Tao et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Allergy Clin Immunol,
doi:10.1016/j.jaci.2020.04.006Orders, An EUA for sotrovimab for treatment of COVID-19, Med Lett Drugs Ther
Osborne, Veigulis, Arreola, Mahajan, Röösli et al., Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration, PLoS One,
doi:10.1371/journal.pone.0246825Pastor-Nieto, Checa-Díaz, González-Muñoz, Martín-Fuentes, Vergara-Sánchez et al., Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain, J Eur Acad Dermatol Venereol,
doi:10.1111/jdv.16798Prabakaran, Zhu, Xiao, Biragyn, Dimitrov et al., Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses, Expert Opin Biol Ther,
doi:10.1517/14712590902763755Ryu, Hong, Lim, Cho, Hwang et al., Clinical features of adult COVID-19 patients without risk factors before and after the nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant outbreak in Korea: experience from Gyeongsangnam-do, J Korean Med Sci,
doi:10.3346/jkms.2021.36.e341Scully, Haverfield, Ursin, Tannenbaum, Klein, Considering how biological sex impacts immune responses and COVID-19 outcomes, Nat Rev Immunol,
doi:10.1038/s41577-020-0348-8Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2035002Yi, Kim, Choe, Hong, Choi et al., SARS-CoV-2 delta variant breakthrough infection and onward secondary transmission in household, J Korean Med Sci,
doi:10.3346/jkms.2022.37.e12Zhou, Yang, Wang, Hu, Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature,
doi:10.1038/s41586-020-2012-7{ 'indexed': { 'date-parts': [[2023, 10, 25]],
'date-time': '2023-10-25T05:49:20Z',
'timestamp': 1698212960639},
'reference-count': 46,
'publisher': 'Korean Academy of Medical Sciences',
'issue': '13',
'license': [ { 'start': { 'date-parts': [[2022, 1, 1]],
'date-time': '2022-01-01T00:00:00Z',
'timestamp': 1640995200000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'}],
'content-domain': {'domain': ['jkms.org'], 'crossmark-restriction': False},
'DOI': '10.3346/jkms.2022.37.e102',
'type': 'journal-article',
'created': {'date-parts': [[2022, 3, 28]], 'date-time': '2022-03-28T23:51:23Z', 'timestamp': 1648511483000},
'update-policy': 'http://dx.doi.org/10.3346/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 6,
'title': 'Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A '
'Retrospective Cohort Study',
'prefix': '10.3346',
'volume': '37',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7016-5124',
'authenticated-orcid': False,
'given': 'Susin',
'family': 'Park',
'sequence': 'first',
'affiliation': [{'name': 'College of Pharmacy, Pusan National University, Busan, Korea.'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0299-5131',
'authenticated-orcid': False,
'given': 'Nam Kyung',
'family': 'Je',
'sequence': 'additional',
'affiliation': [{'name': 'College of Pharmacy, Pusan National University, Busan, Korea.'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-7230-3540',
'authenticated-orcid': False,
'given': 'Dong Wan',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Pulmonology, Department of Internal Medicine, Busan '
'Medical Center, Busan, Korea.'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-4986-4072',
'authenticated-orcid': False,
'given': 'Miran',
'family': 'Park',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Pulmonology, Department of Internal Medicine, Busan '
'Medical Center, Busan, Korea.'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-9534-2921',
'authenticated-orcid': False,
'given': 'Jeonghun',
'family': 'Heo',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Pulmonology, Department of Internal Medicine, Busan '
'Medical Center, Busan, Korea.'}]}],
'member': '1898',
'published-online': {'date-parts': [[2022]]},
'reference': [ { 'issue': '7798',
'key': '10.3346/jkms.2022.37.e102_ref1',
'doi-asserted-by': 'crossref',
'first-page': '270',
'DOI': '10.1038/s41586-020-2012-7',
'volume': '579',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': '10.3346/jkms.2022.37.e102_ref2',
'unstructured': "World Health Organization. Director-general's remarks at the media "
'briefing on 2019-nCoV on 11 February 2020. Updated 2020. Accessed '
'November 1, 2021. '
'http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020'},
{ 'key': '10.3346/jkms.2022.37.e102_ref3',
'unstructured': 'Our World in Data. Statistics and research coronavirus (COVID-19) '
'vaccinations. Updated 2021. Accessed November 1, 2021. '
'https://ourworldindata.org/covid-vaccinations'},
{ 'key': '10.3346/jkms.2022.37.e102_ref4',
'unstructured': 'World Health Organization. COVID-19 weekly epidemiological update. '
'Updated 2021. Accessed November 1, 2021. '
'https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---26-october-2021'},
{ 'key': '10.3346/jkms.2022.37.e102_ref5',
'unstructured': 'Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard by the '
'Center for Systems Science and Engineering (CSSE) at Johns Hopkins '
'University (JHU). Updated 2021. Accessed November 1, 2021. '
'https://coronavirus.jhu.edu/map.html'},
{ 'key': '10.3346/jkms.2022.37.e102_ref6',
'unstructured': 'World Health Organization. Tracking SARS-CoV-2 variants. Updated 2021. '
'Accessed November 1, 2021. '
'https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref7',
'doi-asserted-by': 'crossref',
'first-page': 'e12',
'DOI': '10.3346/jkms.2022.37.e12',
'volume': '37',
'author': 'Yi',
'year': '2022',
'journal-title': 'J Korean Med Sci'},
{ 'issue': '50',
'key': '10.3346/jkms.2022.37.e102_ref8',
'doi-asserted-by': 'crossref',
'first-page': 'e346',
'DOI': '10.3346/jkms.2021.36.e346',
'volume': '36',
'author': 'Lee',
'year': '2021',
'journal-title': 'J Korean Med Sci'},
{ 'issue': '18',
'key': '10.3346/jkms.2022.37.e102_ref9',
'doi-asserted-by': 'crossref',
'first-page': 'e124',
'DOI': '10.3346/jkms.2021.36.e124',
'volume': '36',
'author': 'Jia',
'year': '2021',
'journal-title': 'J Korean Med Sci'},
{ 'issue': '49',
'key': '10.3346/jkms.2022.37.e102_ref10',
'doi-asserted-by': 'crossref',
'first-page': 'e341',
'DOI': '10.3346/jkms.2021.36.e341',
'volume': '36',
'author': 'Ryu',
'year': '2021',
'journal-title': 'J Korean Med Sci'},
{ 'key': '10.3346/jkms.2022.37.e102_ref11',
'unstructured': 'World Health Organization. Therapeutics and COVID-19: living guideline. '
'Updated 2022. Accessed November 1, 2021. '
'https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline'},
{ 'key': '10.3346/jkms.2022.37.e102_ref12',
'unstructured': 'National Institutes of Health. COVID-19 treatment guidelines panel. '
'Coronavirus disease 2019 (COVID-19) treatment guidelines. Updated 2021. '
'Accessed November 1, 2021. '
'https://www.covid19treatmentguidelines.nih.gov/'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref13',
'doi-asserted-by': 'crossref',
'first-page': '2251',
'DOI': '10.1038/s41467-020-16256-y',
'volume': '11',
'author': 'Wang',
'year': '2020',
'journal-title': 'Nat Commun'},
{ 'key': '10.3346/jkms.2022.37.e102_ref14',
'doi-asserted-by': 'crossref',
'first-page': '110337',
'DOI': '10.1016/j.biopha.2020.110337',
'volume': '129',
'author': 'Jahanshahlu',
'year': '2020',
'journal-title': 'Biomed Pharmacother'},
{ 'issue': '11',
'key': '10.3346/jkms.2022.37.e102_ref15',
'doi-asserted-by': 'crossref',
'first-page': '1169',
'DOI': '10.1038/s41590-018-0233-9',
'volume': '19',
'author': 'Saphire',
'year': '2018',
'journal-title': 'Nat Immunol'},
{ 'issue': '3',
'key': '10.3346/jkms.2022.37.e102_ref16',
'doi-asserted-by': 'crossref',
'first-page': '355',
'DOI': '10.1517/14712590902763755',
'volume': '9',
'author': 'Prabakaran',
'year': '2009',
'journal-title': 'Expert Opin Biol Ther'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref17',
'doi-asserted-by': 'crossref',
'first-page': '288',
'DOI': '10.1038/s41467-020-20602-5',
'volume': '12',
'author': 'Kim',
'year': '2021',
'journal-title': 'Nat Commun'},
{'key': '10.3346/jkms.2022.37.e102_ref18', 'author': 'Eom', 'journal-title': 'Res Sq'},
{ 'key': '10.3346/jkms.2022.37.e102_ref19',
'unstructured': 'Ministry of Food and Drug Safety. Approval of Regkirona® Inj., an '
'antibody treatment for COVID-19. Updated 2021. Accessed November 1, '
'2021. '
'https://www.mfds.go.kr/brd/m_99/view.do?seq=45029&srchFr=&srchTo=&srchWord=&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C1009&page=2'},
{ 'key': '10.3346/jkms.2022.37.e102_ref20',
'unstructured': 'Ministry of Food and Drug Safety. Pharmaceutical product information: '
'Regkirona® Inj. 960 mg (regdanvimab). Updated 2021. Accessed November 1, '
'2021. '
'https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202101124'},
{ 'key': '10.3346/jkms.2022.37.e102_ref21',
'unstructured': 'European Medicines Agency. EMA issues advice on use of regdanvimab for '
'treating COVID-19. Updated 2021. Accessed November 1, 2021. '
'https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19'},
{ 'key': '10.3346/jkms.2022.37.e102_ref22',
'unstructured': 'Ministry of Food and Drug Safety. Official approval of Regkirona® Inj., '
'an antibody treatment for COVID-19. Updated 2021. Accessed November 1, '
'2021. '
'https://www.mfds.go.kr/brd/m_99/view.do?seq=45778&srchFr=&srchTo=&srchWord=&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C1009&page=1'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref23',
'doi-asserted-by': 'crossref',
'first-page': '166',
'DOI': '10.3947/ic.2021.0303',
'volume': '53',
'author': 'Kim',
'year': '2021',
'journal-title': 'Infect Chemother'},
{ 'issue': '8',
'key': '10.3346/jkms.2022.37.e102_ref24',
'doi-asserted-by': 'crossref',
'first-page': '1256',
'DOI': '10.1093/infdis/jiaa447',
'volume': '222',
'author': 'Lam',
'year': '2020',
'journal-title': 'J Infect Dis'},
{ 'issue': '2',
'key': '10.3346/jkms.2022.37.e102_ref25',
'doi-asserted-by': 'crossref',
'first-page': '168',
'DOI': '10.1001/jama.2020.11301',
'volume': '324',
'author': 'Fosbøl',
'year': '2020',
'journal-title': 'JAMA'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref26',
'doi-asserted-by': 'crossref',
'first-page': '1325',
'DOI': '10.1038/s41467-021-21553-1',
'volume': '12',
'author': 'Gupta',
'year': '2021',
'journal-title': 'Nat Commun'},
{ 'key': '10.3346/jkms.2022.37.e102_ref27',
'doi-asserted-by': 'crossref',
'first-page': '149',
'DOI': '10.1016/j.amjcard.2020.09.012',
'volume': '136',
'author': 'Daniels',
'year': '2020',
'journal-title': 'Am J Cardiol'},
{ 'issue': '2',
'key': '10.3346/jkms.2022.37.e102_ref28',
'doi-asserted-by': 'crossref',
'first-page': 'e0246825',
'DOI': '10.1371/journal.pone.0246825',
'volume': '16',
'author': 'Osborne',
'year': '2021',
'journal-title': 'PLoS One'},
{ 'issue': '4',
'key': '10.3346/jkms.2022.37.e102_ref29',
'doi-asserted-by': 'crossref',
'first-page': '930',
'DOI': '10.1213/ANE.0000000000005292',
'volume': '132',
'author': 'Chow',
'year': '2021',
'journal-title': 'Anesth Analg'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref30',
'doi-asserted-by': 'crossref',
'first-page': '110',
'DOI': '10.1016/j.jaci.2020.04.006',
'volume': '146',
'author': 'Li',
'year': '2020',
'journal-title': 'J Allergy Clin Immunol'},
{ 'issue': '12',
'key': '10.3346/jkms.2022.37.e102_ref31',
'doi-asserted-by': 'crossref',
'first-page': 'e760',
'DOI': '10.1111/jdv.16798',
'volume': '34',
'author': 'Pastor-Nieto',
'year': '2020',
'journal-title': 'J Eur Acad Dermatol Venereol'},
{ 'issue': '7',
'key': '10.3346/jkms.2022.37.e102_ref32',
'doi-asserted-by': 'crossref',
'first-page': '442',
'DOI': '10.1038/s41577-020-0348-8',
'volume': '20',
'author': 'Scully',
'year': '2020',
'journal-title': 'Nat Rev Immunol'},
{ 'issue': '1',
'key': '10.3346/jkms.2022.37.e102_ref33',
'doi-asserted-by': 'crossref',
'first-page': '29',
'DOI': '10.1186/s13293-020-00304-9',
'volume': '11',
'author': 'Gebhard',
'year': '2020',
'journal-title': 'Biol Sex Differ'},
{ 'issue': '35',
'key': '10.3346/jkms.2022.37.e102_ref34',
'doi-asserted-by': 'crossref',
'first-page': 'e248',
'DOI': '10.3346/jkms.2021.36.e248',
'volume': '36',
'author': 'Moon',
'year': '2021',
'journal-title': 'J Korean Med Sci'},
{ 'key': '10.3346/jkms.2022.37.e102_ref35',
'unstructured': "Clinical Trials Arena. Celltrion's COVID-19 drug regdanvimab meets Phase "
'III endpoints. Updated 2021. Accessed November 1, 2021. '
'https://www.clinicaltrialsarena.com/news/celltrion-regdanvimab-phaseiii-data/'},
{ 'key': '10.3346/jkms.2022.37.e102_ref36',
'unstructured': 'Monoclonal regdanvimab cuts COVID progression risk in placebo trial. '
'IDWeek, September 29-October 3, 2021. Updated 2021. Accessed November 1, '
'2021. https://www.natap.org/2021/IDWeek/IDWeek_43.htm'},
{ 'issue': '1621',
'key': '10.3346/jkms.2022.37.e102_ref37',
'first-page': '49',
'volume': '63',
'year': '2021',
'journal-title': 'Med Lett Drugs Ther'},
{ 'key': '10.3346/jkms.2022.37.e102_ref38',
'unstructured': 'FDA. Fact sheet for health care providers. Emergency Use Authorization '
'(EUA) of bamlanivimab and etesevimab. Updated 2021. Accessed November 1, '
'2021. https://bit.ly/3qfS6DN'},
{ 'issue': '3',
'key': '10.3346/jkms.2022.37.e102_ref39',
'doi-asserted-by': 'crossref',
'first-page': '238',
'DOI': '10.1056/NEJMoa2035002',
'volume': '384',
'author': 'Weinreich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'issue': '1614',
'key': '10.3346/jkms.2022.37.e102_ref40',
'first-page': '201',
'volume': '62',
'year': '2020',
'journal-title': 'Med Lett Drugs Ther'},
{ 'key': '10.3346/jkms.2022.37.e102_ref41',
'unstructured': 'FDA. Fact sheet for health care providers. Emergency Use Authorization '
'(EUA) of casirivimab and imdevimab. Updated 2021. Accessed November 1, '
'2021. '
'http://e-lactancia.org/media/papers/casirivimabimdevimab-DS-FDA-Regeneron2020.pdf'},
{ 'issue': '1627',
'key': '10.3346/jkms.2022.37.e102_ref42',
'first-page': '97',
'volume': '63',
'author': 'Orders',
'year': '2021',
'journal-title': 'Med Lett Drugs Ther'},
{ 'key': '10.3346/jkms.2022.37.e102_ref43',
'unstructured': 'FDA. Fact sheet for health care providers. Emergency Use Authorization '
'(EUA) of sotrovimab. Updated 2021. Accessed November 1, 2021. '
'https://www.fda.gov/media/149534/download'},
{ 'issue': '4',
'key': '10.3346/jkms.2022.37.e102_ref44',
'doi-asserted-by': 'crossref',
'first-page': '628',
'DOI': '10.3390/v13040628',
'volume': '13',
'author': 'Hurt',
'year': '2021',
'journal-title': 'Viruses'},
{ 'issue': '6506',
'key': '10.3346/jkms.2022.37.e102_ref45',
'doi-asserted-by': 'crossref',
'first-page': '1014',
'DOI': '10.1126/science.abd0831',
'volume': '369',
'author': 'Baum',
'year': '2020',
'journal-title': 'Science'},
{ 'key': '10.3346/jkms.2022.37.e102_ref46',
'doi-asserted-by': 'crossref',
'first-page': '135',
'DOI': '10.1016/j.bbrc.2021.06.016',
'volume': '566',
'author': 'Ryu',
'year': '2021',
'journal-title': 'Biochem Biophys Res Commun'}],
'container-title': 'Journal of Korean Medical Science',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://jkms.org/pdf/10.3346/jkms.2022.37.e102',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://jkms.org/DOIx.php?id=10.3346/jkms.2022.37.e102',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://jkms.org/DOIx.php?id=10.3346/jkms.2022.37.e102',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 4, 3]],
'date-time': '2022-04-03T23:59:51Z',
'timestamp': 1649030391000},
'score': 1,
'resource': {'primary': {'URL': 'https://jkms.org/DOIx.php?id=10.3346/jkms.2022.37.e102'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022]]},
'references-count': 46,
'journal-issue': {'issue': '13', 'published-online': {'date-parts': [[2022]]}},
'URL': 'http://dx.doi.org/10.3346/jkms.2022.37.e102',
'relation': {},
'ISSN': ['1011-8934', '1598-6357'],
'subject': ['General Medicine'],
'container-title-short': 'J Korean Med Sci',
'published': {'date-parts': [[2022]]},
'assertion': [ { 'value': '2021-11-18',
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2022-03-14',
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2022-03-29',
'name': 'published_online',
'label': 'Published online',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '© 2022 The Korean Academy of Medical Sciences.',
'name': 'copyright',
'label': 'Copyright',
'group': {'name': 'Copyright_and_licensing', 'label': 'Copyright and Licensing'}},
{ 'value': 'This is an Open Access article distributed under the terms of the Creative '
'Commons Attribution Non-Commercial License '
'(https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted '
'non-commercial use, distribution, and reproduction in any medium, provided the '
'original work is properly cited.',
'name': 'license',
'label': 'License',
'explanation': {'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'},
'group': {'name': 'Copyright_and_licensing', 'label': 'Copyright and Licensing'}}]}
